Accelevir’s mRNA expression assays, mRNA immune response testing, and LNP biodistribution studies provide developers with regulatory-ready data for GLP mRNA testing in both prophylactic and therapeutic programs. From mRNA vaccine T cell assays to Th1/Th2 immune profiling, we deliver high-sensitivity results on low-input clinical samples.
Challenges in mRNA Therapy Development
- Expression verification: Confirming target protein production in vivo.
- Immune response characterization: Measuring T-cell, B-cell, and antibody responses.
- Safety biomarkers: Detecting unwanted inflammatory responses.
- Durability of response: Tracking immune memory over time.
- Sample constraints: Low-volume, time-sensitive specimens in early trials.
How Accelevir Supports mRNA Programs
- Expression Analysis
- qPCR/dPCR for mRNA transcript quantification in tissues and cells.
- Western blot or ELISA (via partners) for protein expression.
- Immunogenicity Monitoring
- ELISpot/ICS for antigen-specific T-cell responses.
- Flow cytometry for B cell phenotyping and germinal center activity.
- Cytokine & Biomarker Profiling
- Multiplex Luminex panels to assess Th1/Th2 balance and inflammation.
- Durability & Memory Assessment
- Longitudinal PBMC-based assays for immune memory tracking.
- Low-Input, Multi-Species Capability
- Optimized workflows for rare sample types and diverse model systems.
Why Partner with Accelevir
- Integrated molecular + immune analysis from a single vendor.
- CLIA-certified, GLP-ready workflows for translational and pivotal studies.
- Expertise in both prophylactic and therapeutic mRNA applications.